Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) finalized the global licensing agreement with 3SBio, Inc. With this agreement, ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the development, production and commercialisation of 3SBio’s bispecific ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

3SBio Inc. Annual stock financials by MarketWatch. View the latest 1530 financial statements, income statements and financial ratios.

He said the 3Sbio deal limited Pfizer’s options. On the bright side, SSGJ-707 is well ahead of LM-299, which Merck said last year was still just enrolling patients for a Phase 1 clinical trial.

3SBio Inc. Annual cash flow by MarketWatch. View 83B net cash flow, operating cash flow, operating expenses and cash dividends.

3SBio (HK: 1530) of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of ...

Chinese biotechnology firm 3SBio , which agreed to be taken private by a group that includes its Chief Executive Jing Lou, said the consortium raised its offer to $16.70 per American Depositary ...